JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Sponsor: Allist Pharmaceuticals, Inc.
A PHASE3 clinical study on Advanced Non-squamous Non-small-cell Lung Cancer and Metastatic Non-squamous Non Small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by Allist Pharmaceuticals, Inc. and has accumulated 7 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE3
-
May 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Oct 2024 — Apr 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting PHASE3
▶ Show 2 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Allist Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Cangzhou, China , Changsha, China , Chengdu, China , Fuzhou, China , Guangzhou, China , Haerbin, China , Hangzhou, China , Hefei, China , Jilin, China and 15 more locations